Mark Sabag - 08 May 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Executive Vice President, International Markets Commercial
Signature
/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag
Issuer symbol
TEVA
Transactions as of
08 May 2025
Net transactions value
-$6,097,304
Form type
4
Filing time
12 May 2025, 16:00:58 UTC
Previous filing
07 Mar 2025
Next filing
11 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sabag Mark Executive Vice President, International Markets Commercial C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL /s/ Dov Bergwerk as attorney-in-fact for Mark Sabag 12 May 2025 0001721442

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Sale $6,097,304 -337,915 -69% $18.04 150,996 08 May 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.865 to $18.265, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

Executive Vice President, International Markets Commercial